An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study.

Although the difference between the two groups did not reach statistical significance ( P -values were 0.254 and 0.273, respectively), it can be seen that the bpCR and tpCR rates for the non-A group were numerically higher than those of the A group ( Fig. 2 a).

also in 111,027 other papers